Elan begins study on new Alzheimer's treatment
Irish biotechnology company Elan has enrolled the first patient in a phase two trial of a drug that could help treat agitation and aggression in patients with Alzheimer’s Disease.
The study aims to evaluate the efficacy, safety and tolerability of an oral treatment called ELND005 over 12 weeks of treatment in patients with moderate to severe Alzheimer’s Disease, who are experiencing at least moderate levels of agitation or aggression, the company said. The study is expected to enroll approximately 400 patients at multiple sites in the US, Canada and other selected regions, it said.
“Agitation/Aggression are common and distressing neuropsychiatric symptoms of Alzheimer’s Disease. These symptoms are a leading cause of patients being placed in nursing homes,” said Dr. Bruno Vellas, chairman of internal and geriatric medicine at University Hospital Toulouse and principal investigator of the European Alzheimer’s Disease Consortium. “Approximately 90 per cent of Alzheimer’s Disease patients develop neuropsychiatric symptoms, and up to 60 per cent develop agitation/aggression over the course of their disease. With no approved therapies for agitation/aggression in most countries, including the US, it is a major treatment problem in Alzheimer’s Disease. This trial is an important step in providing a potential therapy to help manage these symptoms.”
It is currently estimated that approximately 5.4 million Americans and approximately 7.2 million Europeans have Alzheimer’s Disease and these numbers are expected to rise to 16 million by 2050, said Elan.
**Contact desk: firstname.lastname@example.org. Sign up for our [free, daily newsletter](http://newsletter.thepost.ie).**